No	REC Reference Number	IRAS No	Title	First Participant Recruited	Date of First Participant recruited	Date site invited	Date site selected	HRA Approval date	Date site confirmed by sponsor	Date site confirmed	Date site ready to start	A - Permissions delayed/ denied	B - Suspended by Sponsor	C - Closed by Sponsor	D - Sponsor delays	E - Staff Availability issues	F - No Eligible Patients (No patient seen)	G - No Patients Consented	H - Contracting Delays	I-Rare disease	J-Other (Please describe in comments)	Comments	Source of Delay
1	17/LO/1819	210698	BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways	Yes	22/08/2018	30/01/2018	28/06/2018	04/12/2017	18/07/2018	17/07/2018	07/08/2018												
2	17/NS/0018	223787	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms	Yes	22/01/2018	07/09/2017	17/11/2017	11/08/2017	17/11/2017	17/11/2017	13/12/2017												
3	17/YH/0213	210535	A split mouth randomised controlled clinical trial of photodynamic therapy (PDT) as adjunctive therapy to root surface debridement (RSD), compared to RSD alone in the treatment of residual periodontal pockets in patients with chronic periodontitis.	Yes	25/10/2017	19/05/2017	13/10/2017	14/09/2017	13/10/2017	13/10/2017	13/10/2017												
4	18/NW/0236	218224	The AspiRATE study: a proof of concept assessment of a novel intervention to acoustically detect silent aspiration in patients with acquired dysphagia.	Yes	24/05/2018	13/03/2018	08/05/2018	15/05/2018	16/05/2018	16/05/2018	16/05/2018												
5	16/NE/0279	198051	TIDaL: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferativ disorder (PTLD)	Yes	24/04/2018	21/11/2017	05/04/2018	29/09/2016	05/12/2017	05/04/2018	19/04/2018												
6	17/YH/0140	222166	A clinical trial evaluating the feasibility and acceptability of orthotic shorts for walking function in people with multiple sclerosis	Yes	01/02/2018	03/05/2017	15/12/2017	11/12/2017	20/12/2017	07/01/2018	10/01/2018												
7	17/SC/0164	210735	A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation. CRYOSTAT-2 - Early cryoprecipitate in trauma	Yes	27/10/2017	30/03/2017	03/10/2017	26/05/2017	04/10/2017	05/10/2017	10/10/2017												
8	17/SC/0616	232772	A Phase IIb, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of COPD	Yes	19/03/2018	27/09/2017	02/02/2018	11/12/2017	07/02/2018	23/02/2018	28/02/2018												
9	17/NW/0529	226070	Packing of Perianal Abscess Cavities (PPAC)	Yes	14/05/2018	23/08/2017	17/04/2018	05/12/2017	23/02/2018	23/04/2018	24/04/2018												
10	18/SW/0023	238640	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease [SPARK]	No		26/02/2018	06/09/2018	19/02/2018	29/08/2018	07/09/2018													
11	17/LO/1509	232288	A phase 3 randomised, double blind, clinica trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability (MS-STAT2)	Yes	04/09/2018	15/05/2018	10/07/2018	19/01/2018	15/08/2018	21/08/2018	28/08/2018												
12	18/EM/0019	234874	RETurn to work After stroKE: Early vocational rehabilitation compared with usual care for participants: an individually randomised controlled multi-centre pragmatic trial with embedded economic and process evaluations [RETAKE]	Yes	10/07/2018	04/01/2018	01/05/2018	21/02/2018	16/05/2018	24/05/2018	06/06/2018												
13	17/EM/0361	234065	A Multicenter, Randomized, Double-Blind Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies	Yes	20/03/2018	20/09/2017	30/01/2018	11/01/2018	25/01/2018	01/02/2018	22/02/2018												
14	17/WS/0120	225090	A multi-center, double-blind, placebo controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient's self-reported symptoms and their impacts	Yes	17/01/2018	05/10/2017	06/12/2017	24/07/2017	12/12/2017	15/12/2017	22/12/2017												
15	17/YH/0187	218853	PRISM – A randomised Phase II trial of Nivolumab in combination with alternatively scheduled Ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	Yes	03/09/2018	18/01/2018	09/07/2018	11/10/2017	31/05/2018	09/07/2018	12/07/2018												

16	17/YH/0388	235066	A multi-center, double-blind, randomized placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Yes	05/03/2018	26/10/2017	04/01/2018	19/12/2017	16/01/2018	25/01/2018	12/02/2018													
17	17/WM/0239	223251	Ankle Injury Rehabilitation - A multi-centre randomised controlled trial into rehabilitation for ankle fractures [AIR]	Yes	01/12/2017	01/09/2017	20/11/2017	04/07/2017	20/11/2017	30/11/2017	30/11/2017													
18	18/SC/0139	240580	A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced c-KIT/PDGFRA Gastrointestinal Stromal TUmorS who have Received Prior Treatment with Imatinib, Sunitinib, and/or Regorafenib	Yes	02/08/2018	21/11/2017	25/05/2018	05/05/2018	14/06/2018	27/06/2018	26/07/2018													
19	17/YH/0097	221010	Home-based Extended Rehabilitation for Older people (HERO): Individually randomised controlled multi-centre trial to determine the clinical and cost effectiveness of a home-based exercise intervention for older people with frailty as extended rehabilitation following acute illness or injury, including embedded process evaluation.	Yes	31/07/2018	27/04/2018	17/05/2018	25/06/2017	31/05/2018	31/05/2018	07/06/2018													
20	16/SS/0070	202282	PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment.	Yes	22/12/2017	09/06/2017	10/11/2017	02/06/2017	01/12/2017	05/12/2017	08/12/2017													
21	17/YH/0359	233992	Does bowel preparation (either as a single or divided dose) produce better cleansing and diagnostic yield than no preparation at all in small bowel capsule endoscopy	Yes	04/12/2017	14/09/2017	23/11/2017	23/11/2017	23/11/2017	23/11/2017	23/11/2017													
22	17/SC/0142	215503	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	Yes	21/03/2018	23/08/2017	17/01/2018	24/04/2017	12/02/2018	15/02/2018	12/03/2018													
23	17/YH/0355	232541	Acupuncture for post-caesarean itch	Yes	12/02/2018	13/12/2017	13/12/2017	12/12/2017	10/01/2018	10/01/2018	10/01/2018													
24	16/NE/0140	199321	A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases	No		13/09/2017	30/07/2018	12/01/2018	28/06/2018	13/08/2018	11/09/2018													
25	18/NW/0008	231939	A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Countries for Dengue	Yes	10/08/2018	13/03/2018	30/07/2018	26/03/2018	31/07/2018	01/08/2018	08/10/2018													
26	17/NE/0061	215780	COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke	Yes	23/05/2018	01/11/2017	05/04/2018	25/07/2017	03/05/2018	14/05/2018	15/05/2018													
27	17/SC/0391	227067	The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial – H4RT	Yes	20/07/2018	09/02/2018	03/07/2018	07/09/2017	08/05/2018	03/07/2018	04/07/2018													
28	17/SC/0631	218932	Optimising wearable technology for remote diagnosis and monitoring of sleep disorders PHASE I ONLY	No		20/11/2017	17/08/2018	30/01/2018	08/08/2018	17/08/2018	16/10/2018													
29	17/WS/0137	228128	A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)	Yes	26/07/2018	05/01/2018	07/06/2018	27/09/2017	07/06/2018	12/06/2018	20/06/2018													
30	18/YH/0069	242258	A Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [GLOW]	No		06/02/2018	24/07/2018	04/06/2018	11/07/2018	24/07/2018	24/07/2018													
31	17/SC/0602	235629	Behavioural motivation to enhance adherence to oral hygiene recommendations for patients in General Dental Practice	Yes	08/03/2018	01/01/2018	10/01/2018	12/12/2017	05/02/2018	05/02/2018	05/03/2018													
32	18/SC/0210	239572	A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis	No		06/02/2018	07/09/2018	02/08/2018	29/08/2018	10/09/2018	10/09/2018													
33	18/LO/0227	228539	A feasibility study of Acceptance and commitment therapy for people with motor neuron disease (COMMEND)	Yes	25/07/2018	09/03/2018	25/06/2018	13/03/2018	27/06/2018	06/07/2018	09/07/2018													

34	18/WM/0053	236404	A pilot study of personalised biomarker-base treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck	No		22/03/2018	11/09/2018	17/04/2018	25/05/2018	24/09/2018	pending												
35	18/EM/0113	236887	A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis [Galapagos]	No		20/03/2018	16/07/2018	09/05/2018	20/08/2018	24/08/2018	17/09/2018												
36	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy (CORE VNS)	No		04/04/2018	16/09/2018	29/06/2018	20/08/2018	21/09/2018	21/09/2018												
37	18/NE/0214	245998	A single arm, open label multicentre extension study to evaluate the effectiveness and safety of Ocrelizumab in patients with Multiple Sclerosis previously enrolled in a F. Hoffmann La Roche sponsored Ocrelizumab Phase IIIb/IV clinical trial	No		19/03/2018	24/09/2018	11/07/2018	07/09/218	24/09/2018	01/10/2018												
38	17/YH/0394	200610	Clinical Evaluation of Customised Non-Invasive Ventilation interfaces for children (The "COMFORT" study)	No		05/07/2018	12/09/2018	24/08/2018	03/09/2018	13/09/2018	emailed sponsor												
39	18/LO/0144	239494	A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in Patients with Oral Lichen Planus (OLP) using Rivelin®-CLO Patches	No		25/01/2018	29/06/2018	17/05/2018	19/06/2018	03/07/2018	01/10/2018				Y							Sponsor delayed confirmation of study open to recruitment	Sponsor
40	17/YH/0262	219133	TRITON: A randomised, placebo controlled trial to determine the efficacy and mode of action of ondansetron in the treatment of irritable bowel syndrome with diarrhoea	Yes	11/05/2018	20/07/2017	15/12/2017	07/11/2017	14/03/2018	21/12/2017	19/04/2018				Y							Sponsor delayed confirmation of study open to recruitment a site	Sponsor
41	16/NE/0175	203823	A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy.	No		18/07/2016	11/07/2018	01/12/2016	12/07/2018	02/08/2018					Y							Sponsor delayed confirmation of study open to recruitment	Sponsor
42	17/LO/1690	220495	ASTIClite: Autologous Stem cell Transplantation In refractory Crohn's disease - Low Intensity Therapy Evaluation	No		04/12/2017	08/05/2018	15/11/2017	27/04/2018	29/05/2018	11/06/2018						Y					Strict patient eligibility criteria.	Neither
43	16/LO/1099	181655	A randomized phase III trial comparing conventional-dose chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with high-dose chemotherapy using mobilizing Paclitaxel plus Ifosfamide followed by high-dose carboplatin an Etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)	No		12/10/2016	11/12/2017	01/11/2016	21/12/2017	21/12/2017	21/12/2017						Y			Y		Rare disease subpopulation, patients screened but no eligible patients identified.	Neither
44	16/YH/0157	204585	Personalising anal cancer radiotherapy dose – incorporating ACT3, ACT4 and ACT5	Yes	26/06/2018	26/09/2016	29/01/2018	20/07/2016	09/05/2018	23/05/2018	15/06/2018	Y										Relevent permissions delayed and not granted in time.	Neither
45	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	No		22/12/2016	17/10/2017	21/03/2017	24/10/2017	30/10/2017	11/12/2017				Y		Y					Sponsor delayed site intitiatio visit. Patients screened but no eligible patients identified.	Sponsor
46	17/SS/0082	222441	Start or Stop Anticoagulants Randomised Trial (SoSTART)	Yes	24/04/2018	30/10/2017	02/02/2018	05/10/2017	05/03/2018	20/03/2018	16/04/2018				Y				Y			Contracting delays with sponsor, and Sponsor delay i confirmation of study open to recruitment.	Sponsor
47	17/LO/1170	219279	SERENADE: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease	Yes	05/09/2018	04/05/2017	09/10/2017	02/08/2017	19/10/2017	02/11/2017	13/12/2017						Y					Sponsor delayed confirmation of study open to recruitment a site.	Sponsor
48	17/YH/0249	225721	Optimising Behavioural Observation Audiometry (BOA) in Adults with Learning Disabilities	Yes	26/02/2018	05/07/2017	14/11/2017	14/11/2017	16/11/2017	16/11/2017	16/11/2017										Y	Equipment required calibration by manufacturer which was delayed	Neither
49	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma	Yes	12/02/2018	25/04/2017	05/10/2017	25/07/2018	06/10/2017	17/10/2017	03/11/2017						Y			Y		Patients screened but no eligible patients identified. Also rare disease	Neither
50	17/NW/0162	220300	HER2CLIMB – Phase 2 randomised, double-blinded, controlled study of Tucatinib vs placebo in combination with Capecitabine and Trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer	Yes	24/01/2018	02/02/2017	10/10/2017	11/05/2017	11/10/2017	13/10/2017	19/10/2017						Y					No patients seen, strict patien eligibility criteria.	Neither

51	17/LO/1147	222154	A Randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy	Yes	25/01/2018	27/03/2017	09/11/2017	10/08/2017	15/11/2017	21/11/2017	29/12/2017						Y	Y				Strict patient eligibility criteria, eligible patients seen chose not to participate in the study	Neither
52	18/YH/0108	233888	Prolonged enoxaparin in primary percutaneou coronary intervention compared with standard of care therapy -The PENNYWISE feasibility study	Yes	23/08/2018	21/02/2018	13/06/2018	05/06/2018	28/06/2018	28/06/2018	28/06/2018						Y					Patients screened but no eligible patients identified	Neither
53	18/EE/0153	223791	SALivary electro-stimulation for the treatment c dry mouth in patients with Sjogren's syndrome: a multicentRe randomISEd sham-controlled double-blind study (SALRISE)	No		07/03/2018	20/07/2018	20/07/2018	15/08/2018	22/08/2018	09/10/2018				Y							Sponsor delayed confirmation of study open to recruitment.	Sponsor
54	18/LO/0039	232257	Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomised Phase II study of the EORTC Lung Cancer Group	Yes	16/07/2018	17/07/2017	08/02/2018	05/02/2018	29/03/2018	11/05/2018	12/06/2018				Y				Y			Contracting delays, and sponsor delayed confirmation of study open to recruitment.	Sponsor
55	17/EE/0297	225586	A Single-Arm, Multicentre Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients with Inhibitors [STASEY]	Yes	18/01/2018	10/08/2017	07/11/2017	06/09/2017	19/12/2017	21/12/2017	04/01/2018								Y			Contracting delays with sponsor	Sponsor
56	17/NE/0027	215796	CReST 2 - Colorectal Endoscopic Stenting Trial 2	Yes	20/03/2018	05/07/2017	09/11/2017	03/04/2017	30/08/2017	17/11/2017	19/01/2018				Y							Sponsor delayed site intiation visit.	Sponsor
57	16/WM/0451	197521	Pilot Study for a randomised trial comparing the influence of forced air versus resistive fabric warming technologies on post-operative infection rates following orthopaedic implant surgery in adults [RIIiO]	Yes	17/04/2018	13/09/2017	04/10/2017	07/11/2016	05/10/2017	06/10/2017	07/12/2017					Y						NHS Provider staff availability	NHS Provider
58	17/NW/0193	216411	Intraoperative Fluorescence Angiography to Prevent Anastomotic Leak in Rectal Cancer Surgery	No		17/05/2017	12/12/2017	20/04/2017	16/01/2018	25/01/2018	02/02/2018				Y		Y					Sponsor delay in provision of contract, patients screened but no eligible patients identified	Sponsor
59	17/NW/0320	215276	A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis	No		22/02/2018	18/04/2018	15/08/2017	11/05/2018	23/05/2018	06/06/2018						Y					Patients screened but no eligible patients identified.	Neither
60	17/LO/1018	224051	AstraZeneca, D4191C00068, An Open-Label, Multi-Centre, Safety Study of Fixed Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol, 233675	Yes	01/06/2018	21/06/2017	07/12/2017	13/09/2017	13/12/2017	15/12/2017	18/05/2018				Y							Sponsor delayed confirmation of study open to recruitment	Sponsor
61	18/LO/0612	235872	Colchicine and spironolactone in patients with STEMI / synergy stent registry (CLEAR-SYNERGY)	No		03/05/2018	13/08/2018	16/07/2018	13/08/2018	14/08/2018					Y							Sponsor delayed confirmation of study open to recruitment	Sponsor
62	17/LO/0980	219505	HALT: Targeted therapy with or without dose intensified radiotherapy for oilgo-progressive disease in oncegene-addicted lung tumours	Yes	25/05/2018	31/10/2017	18/01/2018	10/07/2017	20/03/2018	12/03/2018	29/03/2018						Y		Y			Contracting delays with NHS Provider. Eligible patients chose not to participate in the study.	NHS Provider
63	16/EM/0436	213166	inhibitor treatment-naïve adult and adolescent patients with Atypical Hemolytic Uremic Syndrome (aHUS)	No		10/08/2017	01/11/2017	07/12/2016	27/10/2017	03/11/2017	20/11/2017						Y					Patients screened but no eligible patients identified	Neither
64	17/EM/0005	215706	A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of on mortality and morbidit in subject with chronic heart failure with reduced ejection fraction (GALACTIC-HF)	Yes	16/03/2018	10/08/2017	07/11/2017	15/02/2017	30/10/2017	08/11/2017	29/11/2017					Y						NHS Provider staff availability	NHS Provider
65	16/SS/0014	187949	A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy	Yes	14/06/2018	03/10/2017	28/03/2018	14/10/2016	12/04/2018	19/04/2018	30/05/2018				Y			Y				Sponsor delayed provision of IMP, eligible patient chose not to participate in the study.	Sponsor
66	17/ES/0122	230938	Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)	Yes	04/09/2018	29/01/2018	04/06/2018	03/11/2017	02/07/2018	06/07/2018	21/08/2018				Y							Sponsor delayed confirmaiton of study open to recruitment	Sponsor
67	17/WS/0147	184216	Precision: Precision-Panc Master Protocol Personalising Treatment for Pancreatic Cancer	No		15/02/2018	14/06/2018	05/01/2018	15/05/2018	09/07/2018	09/07/2018						Y					Strict patient eligibility criteria	Neither

68	17/YH/0390	233236	EFC14867 – A 26-week Randomised, Double-blind, Controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin	No		30/10/2017	18/04/2018	10/01/2018	30/04/2018	02/05/2018	05/06/2018	Y			Y			Y				Sponsor delayed confirmation of study open to recruitment, relevent permissions not issued in time. Eligible patients chose not to participate in this study.	Sponsor
69	17/EE/0340	213113	INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma	No		02/11/2017	26/03/2018	28/11/2017	26/03/2018	16/05/2018	03/07/2018	Y			Y							Relevant internal permissions not granted in time, Sponsor delayed confirmation of study open to recruitment	Both
70	17/LO/1245	208149	A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis (VITA)	Yes	03/07/2018	21/03/2018	20/04/2018	12/09/2017	27/04/2018	08/05/2018	01/06/2018				Y							Sponsor delayed provision of IMP	Sponsor
71	17/EE/0382	220851	PROFILE: PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr trial	No		21/12/2017	18/04/2018	02/11/2017	09/04/2018	17/05/2018	12/06/2018						Y					Patients screened but no eligible patients identified	Neither
72	18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	No		23/04/2018	16/07/2018	28/02/2018	21/05/2018	18/07/2018	23/07/2018						Y					Patients screened but no eligible patients identified	Neither
73	17/WS/0142	221370	PRIMUS 001: A precision PANC clinical study- An adaptive phase 2 study of FOLFOX-A (FOLFOX & nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation	No		19/04/2018	09/07/2018	07/09/2017	16/05/2018	09/07/2018	09/07/2018						Y					Patients screened but no eligible patients identified	Neither
74	17/LO/1623	233895	A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of NGM217 in Adults with Autoimmune Diabetes (SAD Study)	No		28/11/2017	10/07/2018	07/11/2017	07/11/2018	17/07/2018	18/09/2018							Y				Eligible patients chose not to participate in the study due to required admission time.	Neither
75	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	No		13/04/2018	13/04/2018	21/04/2017	13/04/2018	20/04/2018	26/04/2018			Y								Study closed by sponsor at all sites the day after green light	Sponsor
76	17/EM/0077	206480	LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.	No		06/04/2018	29/06/2018	24/07/2017	13/06/2018	06/07/2018	13/09/2018				Y							Sponsor delayed confirmation of study open to recruitment	Sponsor
77	17/NE/0377	233847	A phase 3b, multicentre, prospective, randomized, double blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	No		19/03/2018	04/06/2018	19/02/2018	04/06/2018	07/06/2018	11/06/2018							Y				Eligible patients chose not to participate in the study	Neither
78	16/EM/0380	198726	STUDY 15 – A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)	No		26/03/2018	25/05/2018	09/11/2016	13/07/2018	26/07/2018	09/10/2018	Y			Y							Sponsor delayed confirmation of study open to recruitment. Internal permissions not granted in time.	Both
79	18/LO/0671	240191	An international, multicentre, open-label, randomised, Phase 3 study of BLU-285 vs Regorafenib in patients with locally advanced unresectable or metastatic Gastrointestinal Stromal Tumour (GIST) - Blueprint	No		23/03/2018	17/07/2018	09/05/2018	18/07/2018	24/07/2018	31/08/2018						Y			Y		Rare disease, low recruitment target	Neither
80	18/EE/0067	242431	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A [Pathfinder 8]	No		02/05/2018	27/06/2018	06/04/2018	27/06/2018	05/07/2018	04/10/2018				Y							Sponsor delayed confirmaiton of study open to recruitment	Sponsor
81	18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation in adult patients - a multi-centre randomised controlled trial [ACTIVE]	No		29/03/2018	20/06/2018	13/02/2018	08/06/2018	27/06/2018	05/07/2018						Y					Patients screened but no eligible patients identified	Neither
82	16/WM/0317	206807	RESTORE-BRAIN: Randomised efficacy and safety trial with oral S44819 after recent ischemic cerebral event. An international, multi-centre, randomized, double-blind, placebo controlled phase II study	No		23/03/2018	04/06/2018	07/10/2016	04/06/2018	07/06/2018	16/06/2018							Y				Eligible patients chose not to participate in the trial	Neither